CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 654 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR NHS staff shortages: What’s needed to build a sustainable cancer workforce? October 12, 2020 DeFi Trial: Smart Design and Impressive Results For the Benefit of... September 10, 2022 4 Steps We Can All Take on World Cancer Day to... February 3, 2023 At NCI, A Robust and Rapid Response to the COVID-19 Pandemic April 17, 2020 Load more HOT NEWS Nomination Process for the 2026 ESMO Society Awards Now Open Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers Imaging Test Could Help Guide Breast Cancer Treatment Decisions Patients With DCIS Reduce Risk Of Recurrence And Death If They...
